Axsome Resolves All SUNOSI Patent Litigation, Removing Generic Overhang

What happened

Axsome announced a settlement resolving all SUNOSI patent litigation, following similar agreements with Hikma and Hetero earlier this year, pushing potential generic entry for solriamfetol into the late 2030s or early 2040s. While Sunosi contributed $31.6 million in Q3 2025 (+35% YoY), it remains a secondary asset behind Auvelity, which drove 80% of product revenue. The settlement removes a minor legal overhang but does not address the core investment thesis concerns around Auvelity's growth deceleration and the binary nature of upcoming pipeline catalysts. At a ~$9.5 billion market cap and ~$188 share price, the stock already prices in strong commercial execution and successful Alzheimer's agitation approval, leaving limited upside from this news. The outcome is consistent with prior settlements and was largely anticipated, making it a neutral to modestly positive event that does not shift the fundamental risk/reward profile.

Implication

Sunosi's IP runway is now fully secured through the late 2030s, but the investment case remains dependent on Auvelity growth and the AXS-05 PDUFA. This settlement is incremental and does not alter the asymmetric downside risk at current prices.

Thesis delta

The Sunosi patent resolution was largely expected after earlier settlements and does not change the core thesis. The focus remains on Auvelity's growth trajectory and the April 2026 AXS-05 Alzheimer's agitation decision, which will determine whether the stock can justify its current valuation.